Promising clinical trials surrounding Retatrutide , specifically the 120 milligram formulation branded as ZPHC, suggest a significant impact on body mass loss and associated metabolic illnesses . Scientists anticipate that this combined acting , influencing both GLP-1 and GIP systems, could repr